Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function, that primarily occurs in those 50 years and older. Various causes including genetic susceptibility, environmental risk factors, and exposures have been suggested in the literature. All of these cause repetitive micro-injury to the lung tissue and vasculature, which triggers a cascade of inflammatory response and fibrosis.
IPF affects approximately 132,000 people in the US with about 50,000 new diagnoses every year. However, as the symptoms of IPF are similar to other lung diseases, like asthma and chronic obstructive lung disease (COPD), this results in misdiagnosis of initial presentation. Diagnosis requires a high index of clinical suspicion supported by distinct radiographic and/or histopathologic findings. Median survival is estimated at between 2 and 3 years after diagnosis. Other than lung transplantation, no treatment has shown survival benefit.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market
The Idiopathic Pulmonary Fibrosis market report also covers emerging drugs, current treatment practices, Idiopathic Pulmonary Fibrosis market share of the individual therapies, current and forecasted Idiopathic Pulmonary Fibrosis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Idiopathic Pulmonary Fibrosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Idiopathic Pulmonary Fibrosis Market Key Facts
-
The total prevalent population of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM expected to rise during the study period [2017–2030]. Estimates show the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF) is in the United States followed by the UK.
-
According to DelveInsight’s analysis, it had been observed that Moderate Idiopathic Pulmonary Fibrosis (IPF) cases are more prominent in comparison to Mild and Severe cases across 7 MM.
-
Males have a higher prevalence of Idiopathic Pulmonary Fibrosis as compared to females.
-
Among the European 5 countries, the United Kingdom had the highestprevalent population of Idiopathic Pulmonary Fibrosis (IPF), followed by Italy and Germany. On the other hand, Spain had the lowest prevalent population of IPF.
-
The lowest prevalent population of Idiopathic Pulmonary Fibrosis (IPF) was recorded in Japan.
Key Benefits of Idiopathic Pulmonary Fibrosis Market Report
-
Idiopathic Pulmonary Fibrosis market report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Idiopathic Pulmonary Fibrosis market report will help in developing business strategies by understanding the Idiopathic Pulmonary Fibrosis Market trends & developments, key players and future market competition that will shape and drive the Idiopathic Pulmonary Fibrosis market in the upcoming years.
-
The Idiopathic Pulmonary Fibrosis market report covers Idiopathic Pulmonary Fibrosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Idiopathic Pulmonary Fibrosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Idiopathic Pulmonary Fibrosis Market
The Idiopathic Pulmonary Fibrosis market is expected to increase during the forecast period owing to the increasing prevalent population of Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM.
The Idiopathic Pulmonary Fibrosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Idiopathic Pulmonary Fibrosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Idiopathic Pulmonary Fibrosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Idiopathic Pulmonary Fibrosis Epidemiology
The Idiopathic Pulmonary Fibrosis epidemiology section covers insights about historical and current Idiopathic Pulmonary Fibrosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Idiopathic Pulmonary Fibrosis Drugs Uptake and Key Market Players
The Idiopathic Pulmonary Fibrosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched in the market during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The available therapeutics treatment options in Idiopathic Pulmonary Fibrosis (IPF) Landscape aims to slow the disease progression and not stop the disease to improve survival benefits. To overcome the drawbacks of the treatment many companies are working robustly to identify the cause of disease and targeted therapy.
The key companies in the Idiopathic Pulmonary Fibrosis market include:
FibroGen
Kadmon Corporation
Promedior
Galapagos
MediciNova
And others.
Idiopathic Pulmonary Fibrosis therapies covered in the report include:
Pamrevlumab
KD025
PRM-151
GLPG1690
Tipelukast
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis
4. Idiopathic Pulmonary Fibrosis Market Overview at a Glance
5. Idiopathic Pulmonary Fibrosis Disease Background and Overview
6. Idiopathic Pulmonary Fibrosis Patient Journey
7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population
8. Idiopathic Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Idiopathic Pulmonary Fibrosis Unmet Needs
10. Key Endpoints of Idiopathic Pulmonary Fibrosis Treatment
11. Idiopathic Pulmonary Fibrosis Marketed Products
12. Idiopathic Pulmonary Fibrosis Emerging Therapies
13. Idiopathic Pulmonary Fibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Idiopathic Pulmonary Fibrosis Market Outlook (7 major markets)
16. Idiopathic Pulmonary Fibrosis Access and Reimbursement Overview
17. KOL Views on the Idiopathic Pulmonary Fibrosis Market.
18. Idiopathic Pulmonary Fibrosis Market Drivers
19. Idiopathic Pulmonary Fibrosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Idiopathic Pulmonary Fibrosis Epidemiology Forecast
DelveInsight's Idiopathic Pulmonary Fibrosis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis Pipeline Insights
Idiopathic Pulmonary Fibrosis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects in the Idiopathic Pulmonary Fibrosis market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
